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Abstract
N-acetyl-m-aminophenol (3’-hydroxyacetanilide, AMAP) is the meta isomer of acetaminophen (4’-
hydroxyacetanilide, APAP), the widely used analgesic that is safe at therapeutic doses but is hepatotoxic at
larger doses. Unlike APAP, AMAP does not cause hepatotoxicity in mice even though AMAP and its
metabolites covalently bind to hepatic proteins at levels comparable to APAP. Therefore, comparative studies
with APAP and AMAP have been used in order to investigate mechanisms of toxicity and structure-toxicity
relationships. However, the relationship between AMAP and CYP2E1, the enzyme generally implicated in the
amplification of APAP-induced hepatotoxicity after ethanol ingestion, has not been fully elucidated. The
microsomal metabolism of AMAP to reactive metabolites has been studied however, the identity of the
reactive metabolite(s) of AMAP that bind to CYP2E1 has not been unequivocally determined. Therefore, we
hypothesized that AMAP would covalently bind to and inhibit CYP2E1 in a reconstituted system and that
mass spectral analysis would provide structural information for the reactive metabolite. Deconvoluted mass
spectra indicated that a reactive metabolite of AMAP forms mono- and diadducts with CYP2E1 apoprotein
(experimentally measured masses = 54622.4 ± 8.9 Da, 54791.3 ± 6.1 Da, and 54451.7 ± 5.5 Da, respectively)
but not to other incubation components (i.e., heme, cytochrome b5, or cytochrome P450 reductase).
NADPH was required for adduct formation while glutathione prevented it. The data indicated that reactive
metabolite formation probably involves the addition of one oxygen atom to AMAP (MWAMAP = 151.2 Da;
MWoxidized AMAP = 151.2 + 16.0 = 167.2 Da; experimentally determined mass of the small molecule
adducted to CYP2E1 = 167.5 ± 7.1 Da. Therefore, the reactive metabolite of AMAP that covalently binds to
CYP2E1 is likely formed from aromatic oxidation (quinone formation).
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Results 
1. Inactivation of human CYP2E1 mediated chlorzoxazone hydroxylase activity following 
pre-incubation with AMAP and NADPH.  Data points are the average of at least three 
experiments conducted on separate days. 
 
 
 
 
 
 
 
 
 
 
2. Remaining chlorzoxazone hydroxylase activity following 72 minutes preincubation.  
Values are the average of two experiments conducted in triplicate on separate days. 
   Pre-Incubation Components    % Control Activity 
   2E1 Supersomes      100 (12.2 ± 0.5 pmol/min/pmol) 
     + NADPH           88.5 ± 2.6      
     + 2.5 mM AMAP          98.6 ± 2.5 
      + 20 mM AMAP        89.2 ± 2.8  
     + 40 mM AMAP          65.6 ± 2.6 
    + 20 mM AMAP, + NADPH        64.7 ± 6.2  
    + 20 mM AMAP, + NADPH, + 5 mM GSH   91.2 ± 2.9 
    + 40 mM AMAP, + NADPH      43.4 ± 3.4 
    + ABT, + NADPH       < 1 
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Introduction 
• To reduce the risk of potential drug-drug interactions (DDIs) new chemical entities 
(NCEs) are commonly assessed for time dependent inhibition of major drug 
metabolizing enzymes (Grimm SW et al (2009) Drug Metabolism and Disposition 37: 
1355-1370).  
 
• Whereas time dependent inhibition (TDI) is typically an undesired characteristic for 
prospective drugs, a time dependent inhibitor can be a useful tool to generate new 
information about protein structure-function relationships. 
 
Previous studies suggest N-acetyl-m-aminophenol may be an effective probe of 
human CYP2E1.    
• N-Acetyl-m-aminophenol (3’-hydroxyacetanilide, AMAP) is the meta isomer of 
acetaminophen (4’-hydroxyacetanilide, APAP), the widely used analgesic that is 
hepatotoxic in overdose situations.  Unlike APAP, AMAP does not cause hepatotoxicity 
in mice even though AMAP and its metabolites covalently bind to hepatic proteins at 
levels comparable to APAP (Nelson EB (1980) Res Commun Chem Pathol Pharmacol 
28:447-456).   
 
 
 
 
 
• p-Nitrophenol hydroxylase activity is decreased in mouse liver microsomes and an 
anti-arylacetamide antibody identified a 50-kDa protein that comigrated with CYP2E1 
from AMAP-treated mice (Halmes NC, Samokyszyn VM, Hinton TW, Hinson JA, and 
Pumford NR (1998) Toxicol Letters 94:65-71.        
 
• Mass spectra of human CYP2E1-AMAP                                                                                 
adducts generated from reconstituted                                                                                    
CYP2E1 indicate a reactive metabolite                                                                                         
of AMAP forms mono- and diadducts                                                                                          
with CYP2E1.   
 
 
 
 
 
 
 
Introduction 
• Table of detected masses for                                                                         
CYP2E1, cytochrome P450                                                                               
reductase, cytochrome b5, and                                                                          
heme analyzed under various                                                                                     
incubation conditions:  
 
• Mass spectra indicate adduct                                                                                                 
formation is NADPH dependent                                                                                                                
and specific for CYP2E1 in the                                                                                         
reconstituted system. 
 
Conclusions 
1. Inhibition data is consistent with mass spectral data:  
• Mass spectra indicated CYP2E1-AMAP adduct formation is NADPH dependent. 
• Inhibition of chlorzoxazone hydroxylase activity is NADPH dependent. 
• Glutathione protects CYP2E1 from inactivation. 
• Mass spectral data indicated metabolite formation involves the addition of one 
oxygen atom to AMAP (MWAMAP = 151.2 Da; MWoxidized AMAP = 151.2 + 16.0 = 
167.2 Da; experimentally determined mass of the small molecule adducted to 
CYP2E1 = 167.5 ± 7.1 Da (n = 3).  
 
 
 
 
 
 
 
 
2. Mass spectral data, KI, and lag period prior to inactivation all support a multi-step 
activation process involving aromatic hydroxylation followed by a second oxidative 
event to form a reactive quinone and is consistent with evidence from metabolite 
identification studies of AMAP glutathione conjugates (Streeter AJ, Bjorge SM, 
Axworthy DB, Nelson SD, and Baillie TA (1984) Drug Metab Dispos 12:565-576. 
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Research Objective 
Characterize CYP2E1-AMAP interactions and assess the utility of AMAP as a probe of 
human CYP2E1 structure-function by testing for mechanism-based inactivation. 
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Results 
3.  1/kobs versus 1/[AMAP] 
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KI  = 4.9 mM 
kinact  = 0.005 min
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